Advertisement

Volume 132, Issue 25

 

 

December 20, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Nuclear retention of FOXO1 as an oncogenic event in Burkitt lymphoma. See the article by Kabrani et al.

Temporal autoregulation during human PU.1 locus SubTAD formation
This paper reports a link between PU.1 and the looping factor LDB1 that acts as a novel mechanism of PU.1 regulation in myeloid differentiation.


Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells
The authors report that the retained nuclear localization of the transcription factor FOXO1 (forkhead box class O1) is a lymphoma-promoting, oncogenic event in the pathogenesis of Burkitt lymphoma.


Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?
In this Perspective, also this month’s CME article, the authors discuss various aspects of the involvement of the coagulation cascade and platelets with the formation of intraluminal thrombus, the contribution of nonocclusive thrombus to stability of the aortic wall, and the possible role of antithrombotic therapy in patients with abdominal aortic aneurysm.


Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
The authors present the detailed final results regarding clinical end points of the phase IIIrandomized study of the combination of eltrombopag and azacitidine compared to standard azacitidine in high-grade myelodysplastic syndromes (MDSs).


Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
The authors report the results of long-term follow up and subsequent therapies of the practice-changing AETHERA trial of brentuximab vedotin in Hodgkin lymphoma.


BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
The investigators examine the potential therapeutic utility of BH3 mimetics and study the dependency of primary myeloma on BCL2, BCLXL, and MCL1.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.